CAS 517-28-2|Hematoxylin

[1]. EF Kingston, et al. Vascular invasion is underrecognized in colorectal cancer using conventional hematoxylin and eosin staining. 《Diseases of the Colon & Rectum》, 2007, 50(11):1867-1872

[2]. JE Grilley-Olson, et al. Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets.

[3]. HR Zare, et al. Simultaneous determination of ascorbic acid, adrenaline and uric acid at a hematoxylin multi-wall carbon nanotube modified glassy carbon electrode. Sensors & Actuators B Chemical, 2010, 143(2):666-672

CHEMICAL IDENTIFICATION

RTECS NUMBER :

MH7875000

CHEMICAL NAME :

Hematoxylin

CAS REGISTRY NUMBER :

517-28-2

LAST UPDATED :

199709

DATA ITEMS CITED :

4

MOLECULAR FORMULA :

C16-H14-O6

MOLECULAR WEIGHT :

302.30

WISWESSER LINE NOTATION :

T C6 B566 LO&TT&J EQ FQ JQ NQ OQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

400 mg/kg/26W-C

TOXIC EFFECTS :

Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - lymphoma, including Hodgkin's disease

REFERENCE :

GASTAB Gastroenterology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1943- Volume(issue)/page/year: 23,1,1953 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 80980 No. of Facilities: 667 (estimated) No. of Industries: 3 No. of Occupations: 6 No. of Employees: 3015 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 80980 No. of Facilities: 1405 (estimated) No. of Industries: 3 No. of Occupations: 11 No. of Employees: 24188 (estimated) No. of Female Employees: 20340 (estimated)

Cancer Res. 75(6) , 1102-12, (2015)

The translation initiation factor eIF4E is an oncogene that is commonly overexpressed in primary breast cancers and metastases. In this article, we report that a pharmacologic inhibitor of eIF4E funct...

Hum. Gene Ther. 26(3) , 172-82, (2015)

Intrauterine growth restriction (IUGR) due to placental insufficiency is a leading cause of perinatal complications for which there is no effective prenatal therapy. We have previously demonstrated th...

Autophagy 10(7) , 1241-55, (2014)

Glioblastoma is one of the most aggressive human cancers with poor prognosis, and therefore a critical need exists for novel therapeutic strategies for management of glioblastoma patients. Itraconazol...